Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05006716 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 614
- Enrollment target
- 20
- Study locations
NCT05006716 is a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 614 participants, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (243% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05006716, a Phase 1 study of Chronic Lymphocytic Leukemia and Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 614 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Conditions Studied
Interventions
- DRUG BGB-16673
Study Locations (20)
Arizona
- Mayo Clinic Phoenix - Phoenix
- Honor Health Research Institute - Scottsdale
- University of Arizona Cancer Center - Tucson
California
- University of California San Diego (Ucsd) Moores Cancer Center - La Jolla
- Stanford Medicine - Palo Alto
- UCLA Santa Monica Cancer Care - Santa Monica
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Tampa General Hospital Cancer Institute - Tampa
Georgia
- Augusta University - Augusta
- Southeastern Regional Medical Center - Newnan
Alabama
- University of Alabama At Birmingham Hospital - Birmingham
Colorado
- Uchealth North - Fort Collins
Illinois
- Midwestern Regional Medical Center - Zion
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2029-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05006716
The ClinicalTrials.gov registry entry for NCT05006716 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (243% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which BGB-16673 is the first listed.
NCT05006716 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05006716 about?
NCT05006716 is a clinical study titled "A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies". Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
What is the current status of trial NCT05006716?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 614 participants. The study started on 2021-09-13. Estimated completion is 2029-11.
What conditions does trial NCT05006716 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma.
What interventions are being tested in trial NCT05006716?
The interventions under investigation include: BGB-16673 (DRUG).
Who is sponsoring clinical trial NCT05006716?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05006716 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.